Paper Details

  1. Home
  2. Paper Details

Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group.

Author:

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

This study investigated the effectiveness of laser treatment for a condition called choroidal neovascular membrane (CNVM) in eyes with age-related macular degeneration, ocular histoplasmosis, or unknown causes. After 3 years, laser treatment significantly reduced the risk of severe vision loss compared to no treatment, particularly for patients with ocular histoplasmosis. The study concludes that laser treatment is effective in preventing vision loss from CNVM, and ongoing research is assessing its effectiveness over 5 years.
Paper Details　
Original Abstract of the Article :
The Macular Photocoagulation Study randomized controlled clinical trials designed to determine whether argon laser photocoagulation is effective for preventing or delaying severe visual loss in eyes with an extrafoveal choroidal neovascular membrane secondary to senile macular degeneration (Senile M...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/2423061

データ提供：米国国立医学図書館（NLM）

Argon Laser Photocoagulation for Neovascular Maculopathy

Ophthalmology is a fascinating field, and I find it incredibly captivating how researchers continue to develop new treatments for vision-threatening conditions like neovascular maculopathy. This study delves into the effectiveness of argon laser photocoagulation, a technique that uses a laser to seal leaking blood vessels in the eye, for preventing or delaying vision loss in patients with neovascular maculopathy.

The Effectiveness of Argon Laser Photocoagulation

This study provides strong evidence that argon laser photocoagulation can significantly reduce the risk of severe vision loss in patients with neovascular maculopathy. The results show that treatment with argon laser was associated with a lower risk of vision loss compared to no treatment, demonstrating the technique's effectiveness in preserving vision.

Protecting Your Vision

This study underscores the importance of early detection and treatment for neovascular maculopathy. If you experience any vision changes, it's essential to consult an ophthalmologist promptly. Early diagnosis and treatment can significantly improve outcomes and protect your vision.

Dr. Camel's Conclusion

Argon laser photocoagulation is like a refreshing oasis in the desert of vision loss, offering hope for patients with neovascular maculopathy. This study serves as a reminder that advancements in medical technology can provide effective solutions to challenging eye conditions.

Date :
  1. Date Completed 1986-06-02
  2. Date Revised 2015-04-17
Further Info :

Pubmed ID

2423061

DOI: Digital Object Identifier

2423061

Related Literature

Article Analysis
・Effective treatment of macular degeneration
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.